-
Sale!
Comprehensive regulation-by-regulation analysis of FDA CFR Part 211 Subpart E (Control of Components and Drug Product Containers and Closures) with direct links to Form 483 observations and Warning Letters from 2017-2025. -
Sale!
Comprehensive packaging and labeling enforcement data 2017-2025 -
Sale!
FDA enforcement citation analysis for 21 CFR Part 820 Subpart K – Labeling and Packaging Control (§820.120 Device labeling, §820.130 Device packaging). Form 483 observations and Warning Letters 2017–2025. -
Sale!
FDA enforcement citation analysis for 21 CFR Part 820 Subpart L – Handling, Storage, Distribution, and Installation (§820.140, §820.150, §820.160, §820.170). Form 483 observations and Warning Letters 2017–2025. -
Sale!
FDA enforcement citation analysis for 21 CFR Part 820 Subpart N – Servicing (§820.200) and Subpart O – Statistical Techniques (§820.250). Form 483 observations and Warning Letters 2017–2025. -
Sale!
Comprehensive cGMP framework covering quality standards digital transformation and cybersecurity in 2025. -
Sale!
Comprehensive framework for ALCOA++ compliance and regulatory expectations in data integrity programs. -
Sale!
Strategic insights on design controls, cybersecurity, and QMSR transition for medical device manufacturers navigating AI-enabled technologies. -
Sale!
Strategic approach to medical device quality system improvements addressing QMSR harmonization and cybersecurity requirements. -
Sale!
Framework for establishing and implementing KPIs to drive quality management system continuous improvement and organizational excellence.


